CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Caliway Biopharmaceuticals Co Ltd is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Caliway Biopharmaceuticals Co Ltd
32F-9, No.99, Section 1,
Xintai 5th Road, Xizhi District
Phone: +886 226971355p:+886 226971355 TAIPEI, 221  Taiwan Ticker: 69196919
Business Summary
Caliway Biopharmaceuticals Co Ltd is a Taiwan-based company primarily engaged in the development of new drugs for medical aesthetics, chronic inflammatory diseases, and aging. The Company's products include CBL-514, mainly used for non-surgical localized fat reduction and improvement of cellulite; CBL-514D, mainly used to treat Sclerosis and sleep apnea; CBA-539, mainly used for pigmentation, skin whitening, and anti-aging; and CBF-520, mainly used to treat central obesity. The Company sells its products in domestic and international markets, with the United States, Canada, China, and Europe as the primary regions.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-Yes---

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
12/31/202512/31/2025Yes----

Industries
SIC Code Description
5122 Drugs, drug proprietaries, and druggists' sundries
2834 Pharmaceutical preparations

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Chairman of the Board, Chief Strategy Officer Lu-HuiHsu 5/5/2025 10/22/2012
Chief Executive Officer, Chief Research & Development Officer, Director VivianLing 11/7/2025 10/22/2012
Manager of Finance & Accounting Division Tsung-LinWang 2/24/2026 2/7/2025
8 additional Officers and Directors records available in full report.

General Information
Outstanding Shares: 1,552,977,000 (As of 12/31/2025)
Shareholders: 7,903
Stock Exchange: TPE
Fax Number: +886 226972508


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Thursday, March 19, 2026